In the phase 1 AVID200‐03 dose‐escalation study (NCT03834662), proinflammatory serum marker levels were increased in a dose‐dependent manner in patients (N = 19) receiving AVID200; tumor biopsies showed modulation of TGF‐β signaling and immune activation [48]. Here, TGFB1 is linked to neoplasm.